Novavax | NVAX - Operating Profit


Novavax reported $20.94M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Adma Biologics USD 62.75M 11.74M Dec/2025
Agenus USD 14.4M 19.26M Dec/2025
AstraZeneca USD 7.11B 4.14B Mar/2026
BioCryst Pharmaceuticals USD 260.38M 230.79M Dec/2025
Cassava Sciences USD -13.55M 1.69M Dec/2025
Geron USD -10.79M 3.1M Dec/2025
GlaxoSmithKline GBP 2.29B 856M Mar/2026
MannKind USD -69.24M 28.19M Dec/2025
Merck USD -1.88B 8.12B Mar/2026
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Moderna USD -1.39B 531M Mar/2026
Novartis USD 4.06B 521M Dec/2025
Novavax USD 20.94M 100.32M Dec/2025
Pfizer USD 4.65B 3.99B Dec/2025
Sanofi EUR 1.94B 239M Mar/2026
Sarepta Therapeutics USD -410.08M 347.2M Dec/2025
TG Therapeutics USD 50.49M 21.13M Dec/2025